Mouse myeloma cell line NS0-derived recombinant human LAIR1 isoform 1 Gln22-His163 Accession # Q6GTX8
Detects human LAIR1 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 15% cross-reactivity with recombinant human LAIR2 is observed and less than 2% cross-reactivity with recombinant mouse LAIR1 is observed.
Details of Functionality
ActivityAssaywCitation not found None None
Test in a species/application not listed above to receive a full credit towards a future purchase.
Leukocyte-associated Ig-like receptor-1 (LAIR1; also CD305) is a 46 kDa inhibitory receptor belonging to the Ig superfamily. It is
a type I transmembrane protein with one extracellular Ig-like domain
and two cytoplasmic ITIMs. Four LAIR-1 splice variants exist. LAIR1b
has a 17 aa deletion outside the Ig loop in the extracellular domain.
It differs from LAIR1c by one aa residue. LAIR1d has a 77 aa truncation
in the cytoplasmic domain. LAIR1 is expressed on NK cells, T cells, B
cells, monocytes, dendritic cells and most thymocytes. The
extracellular domain of human LAIR1 shares 40% aa identity with that of
the mouse protein.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.